BIIBBiogen
Price
+57%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, nothing alarming, price roughly fair, growth fading, the market undecided.
Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA, co-developed treatments to address a defining pathology of Alzheimer’s disease and launched the first approved treatment to target a genetic cause of ALS.
In the company’s own words · 10-K filed Feb 6, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Biogen (BIIB) reported revenue of $2.48B in Q1 2026 (quarter ended Mar 31, 2026), up 1.9% from the same quarter a year earlier. That came with a gross margin of 73% and net income of $320M (13% of revenue). For the full year FY2025, revenue was $9.89B (+2.2% year on year) and net income $1.29B. Its largest product in Jun 2026 was Royalty Attributed To OCREVUS at $381M, 13% of the disclosed total, just ahead of Rare Disease Product at 10.0%. The next results filing is expected around Oct 29, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jul 29, 2026Cambridge, Mass. – July 29, 2026.Earnings release · press release
- May 14, 2026CVR Agreement As previously disclosed, on March 31, 2026, Biogen Inc., a Delaware corporation (“Biogen”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Apellis Pharmaceuticals, Inc., a Delaware corporation (“Apellis”), and Aspen Purchaser Sub, Inc., a Delaware corporation and a wholly …Material agreement entered · Form 8-K
- Mar 31, 2026Agreement and Plan of Merger On March 31, 2026, Biogen Inc., a Delaware corporation (“Biogen”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Apellis Pharmaceuticals, Inc., a Delaware corporation (“Apellis”), and Aspen Purchaser Sub, Inc., a Delaware corporation and a wholly owned …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $2.95BThe company’s own SEC segment disclosure.
- Royalty Attributed To OCREVUS$381.4M13%
- Rare Disease Product$294.9M10%
- Tysabri Product$270.5M9%
- Product And Service Other$242.4M8%
- Contract Manufacturing And Other$232.4M8%
- Fumarate$204.4M7%
- Other (18)$1.33B45%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, General
The closest names by size in the same industry